-
1 day ago | 
consultantlive.com | Lana Pine
For many clinicians, metabolic dysfunction-associated steatohepatitis (MASH) — formerly known as NASH — presents a diagnostic and management challenge. Dianne Gillard’s story, a U.K.-based patient advocate, highlights the real-world consequences of missed diagnostic opportunities and underscores the need for earlier detection, patient-centered communication, and system-wide changes in fatty liver disease screening.
-
1 day ago | 
hcplive.com | Lana Pine
Fatty liver disease is a growing public health crisis — yet it often remains undetected until catastrophic events force a diagnosis. Jerry Rosenberg’s story is a powerful reminder of this reality and offers key takeaways for physicians working at the intersection of primary care, hepatology, critical care, and transplant medicine.
-
3 days ago | 
theeducatedpatient.com | Lana Pine
For John D. Ortiz, DHSc, RPFT, a professor at the Loyola University Chicago’s Parkinson School of Health Sciences and Public Health, kidney disease wasn’t something he felt — it was something he discovered by chance during a routine checkup at age 43. At the time, he felt healthy and was physically active. But a blood test revealed that his kidneys were only working at about 50% capacity.
-
3 days ago | 
theeducatedpatient.com | Lana Pine
As summer temperatures climb, so do the challenges for people living with asthma. From air pollution and heat to wildfire smoke and shifting activity routines, managing asthma during the warmer months requires extra attention. In an interview with The Educated Patient, Reynold A.
-
3 days ago | 
theeducatedpatient.com | Lana Pine
Today marks the final installment of our 3-part series on liver health in partnership with the Global Liver Institute (GLI), and we’re closing with conversation featuring Jennifer Lai, M.D., a general and transplant hepatologist and board-certified Physician Nutrition Specialist at UCSF. Lai cares for patients across the full spectrum of liver disease and brings a unique, research-informed perspective to the role that nutrition plays in protecting liver health.
-
4 days ago | 
theeducatedpatient.com | Lana Pine
In a new study of over 700 women aged 18 to 34, investigators found that those with attention-deficit hyperactivity disorder (ADHD) were significantly more likely to experience premenstrual dysphoric disorder (PMDD), a severe form of premenstrual syndrome (PMS) that causes intense mood changes, irritability, depression and anxiety before a menstrual period. ADHD is often underdiagnosed in girls and women.
-
4 days ago | 
theeducatedpatient.com | Lana Pine
The U.S. Food and Drug Administration (FDA) has officially cleared the Happy Ring as a class II medical device to help diagnose sleep apnea, insomnia and other sleep-related conditions — all from the comfort of home. "Sleep is the foundation of health and the 'canary in the coal mine' of disease," said Dustin Freckleton, M.D., founder and CEO of the Austin-based digital-health company Happy Health.
-
4 days ago | 
theeducatedpatient.com | Lana Pine
Welcome to Day 2 of our special three-part series on fatty liver disease, created in partnership with the Global Liver Institute (GLI). Today, we spotlight Dianne Gillard, a passionate patient advocate from the U.K. whose diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) came nearly two decades after her first symptoms.
-
5 days ago | 
theeducatedpatient.com | Lana Pine
A low FODMAP diet significantly reduced gastrointestinal (GI) symptoms in women with endometriosis and improved their quality of life, according to a study published in Alimentary Pharmacology and Therapeutics. Many women living with endometriosis — a condition that affects one in seven women living in Australia, where the study took place — experience frequent and disruptive GI symptoms including bloating, abdominal pain and irregular bowel habits.
-
5 days ago | 
theeducatedpatient.com | Lana Pine
Compass Pathways has announced positive findings from a pivotal phase 3 trial evaluating its synthetic psilocybin treatment, COMP360, for people with treatment-resistant depression. This is the first-ever Phase 3 trial of a classic psychedelic to report successful results, marking a major milestone in mental health research.
